German generics drugmaker STADA Arzneimittel (SAZ: Xetra) has reported 11% growth in sales in its annual 2022 results statement, propelled by “numerous launches and line extensions, market-share gains and strong supply reliability.”
The firm’s consumer healthcare and specialty drug businesses were key growth drivers in 2022, with revenues reaching 3.8 billion euros ($4 billion) overall.
The earnings before interest, tax, depreciation and amortization (EBITDA) figure improved by 17%, reaching 875 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze